News Conference News Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices L.A. McKeown November 18, 2022
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
Presentation TCT 2022 Stent-Free PCI (DCB Only Approach): Insights and Considerations from the SELUTION de NOVO Randomized Control Study Presenter: Christian M. Spaulding September 17, 2022
News Industry News TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism September 13, 2022
News Daily News Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy L.A. McKeown June 01, 2022
News Conference News SCAI 2022 DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year L.A. McKeown May 23, 2022
News Conference News SCAI 2022 SAFE-PAD Provides More Long-term Safety Data for Paclitaxel L.A. McKeown May 22, 2022
News Conference News ACC 2022 Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD L.A. McKeown April 04, 2022
News Daily News Routine IVUS in Peripheral Interventions Supported by Small RCT L.A. McKeown March 09, 2022